PET Scans and Liquid Biopsies Offer Safe Path to Skip Chemotherapy in Early Breast Cancer
Global Economic Times Reporter
korocamia@naver.com | 2026-11-21 10:33:47
Five-year data from the PHERGain trial published in Nature Medicine show durable survival rates for HER2-positive patients treated with targeted antibodies alone, while blood-based biomarkers sharpen recurrence risk assessments.
MADRID — Selected patients with early-stage HER2-positive breast cancer can safely bypass conventional chemotherapy without compromising long-term survival, according to five-year follow-up results from an international clinical trial.
By combining functional positron emission tomography (PET) imaging with surgical pathology assessments, researchers successfully tailored treatment intensity to each tumor’s early biological response—sparing roughly one-third of patients in the experimental cohort from the toxic side effects of cytotoxic drugs.
The findings, led by Dr. José Manuel Pérez-García, Dr. Javier Cortés, and colleagues across Europe, were published online in the journal Nature Medicine.
Adapting Therapy Through Early Imaging
Standard neoadjuvant (pre-surgical) care for operable HER2-positive breast cancer typically combines dual HER2-targeted antibodies—trastuzumab and pertuzumab—with potent chemotherapy regimens. While highly effective, systemic chemotherapy carries substantial risks of short- and long-term toxicity.
To test whether a response-adapted approach could safely de-escalate care, the randomized, open-label phase 2 PHERGain trial enrolled patients with centrally confirmed, stage I to IIIA HER2-positive breast cancer measuring at least 1.5 centimeters. Participants were assigned either to standard chemo-immunotherapy (Group A) or to an adaptive strategy (Group B) that started solely with trastuzumab and pertuzumab, alongside endocrine therapy for hormone receptor-positive tumors.
After two cycles of targeted therapy, patients in the adaptive arm underwent F-FDG-PET scans. Those whose tumors showed an early metabolic response—defined as a reduction of at least 40% in maximum standardized uptake value—continued on chemotherapy-free antibody treatment until surgery. Non-responders, as well as metabolic responders who still had residual invasive cancer at surgery, were escalated to receive docetaxel and carboplatin chemotherapy.
Durable Five-Year Outcomes
At a median follow-up of 5.6 years, the five-year invasive disease-free survival (iDFS) rate across the 267 protocol-treated surgical patients in the PET-guided group reached 89.5%, compared with 96.7% among the 63 surgical patients in the standard chemotherapy arm. Overall survival at five years remained virtually identical across the broader randomized cohorts, standing at 98.1% for the adaptive strategy and 98.4% for standard therapy.
Most notably, among the 86 patients who achieved both an early PET metabolic response and a pathological complete response (pCR)—meaning no viable cancer cells were found at surgery—without ever receiving chemotherapy, the five-year iDFS rate was 92.4%, with only a single case of distant metastasis recorded.
Blood Biomarkers Refine Risk Stratification
In an exploratory analysis, investigators also tracked circulating tumor DNA (ctDNA) using liquid biopsies collected before treatment, after two cycles, and prior to surgery. Baseline ctDNA was detectable in 71.0% of evaluable patients, correlating strongly with disease severity—rising from 33.3% in stage I disease to 93.2% in stage III tumors.
Tracking ctDNA dynamics proved highly informative:
Treatment Response: Patients whose ctDNA cleared early after two treatment cycles achieved a pCR rate more than double that of patients with persistent ctDNA (48.4% versus 22.0%). Early molecular clearance also aligned closely with PET imaging responses, occurring in 90.5% of metabolic responders.
Surgical Prediction: None of the 28 patients who still had detectable ctDNA immediately before surgery achieved a pathological complete response.
Long-Term Prognosis: Patients with detectable baseline ctDNA faced a significantly lower five-year iDFS than those without detectable levels (86.7% versus 97.1%). While early ctDNA clearance also tracked with better five-year disease-free survival (92.3% versus 75.6%), its independent statistical significance diminished after adjusting for tumor stage and lymph node involvement.
Caveats Before Routine Clinical Adoption
Despite the encouraging long-term data, oncologists caution that the strategy is not yet ready to replace standard care across all clinics. Because PHERGain was designed as a non-comparative phase 2 study, it was not statistically powered to prove formal equivalence between chemotherapy omission and standard chemo-immunotherapy. Furthermore, researchers note that the 92.4% survival figure for the chemotherapy-free pCR group reflects a subgroup defined after randomization, meaning it should be viewed as descriptive rather than definitive proof of causal benefit.
Additionally, the trial was initiated before adjuvant trastuzumab emtansine (T-DM1) became the standard post-surgical therapy for patients with residual disease—a treatment advance that would likely improve outcomes even further today.
Still, the study authors conclude that integrating functional PET imaging, pathological assessment, and liquid biopsy monitoring provides a compelling blueprint for future prospective trials aimed at sparing breast cancer patients unnecessary toxicity without sacrificing cure rates.
[ⓒ Global Economic Times. 무단전재-재배포 금지]
WEEKLY HOT
- 1Picayune’s Pearl River County SPCA Brings Low-Cost Pet Vaccines and Microchipping to Crosby Commons
- 2Mars Commits £161 Million to Overhaul Historic UK Pet Food Plant with Recyclable Packaging Lines
- 3The Growing Divide at the Vet’s Office: Rising Costs, Hurt Feelings, and Burnout
- 4PET Scans and Liquid Biopsies Offer Safe Path to Skip Chemotherapy in Early Breast Cancer
- 5Small Pets Boost Kids’ Mental Health, While Early Cat Ownership Shows Unexpected Risks, Study Finds
- 6Grief Turned to Outrage: Philippine Pet Cremation Scandal Sparks Fraud Charges and Calls for Legal Reform